Scope and patent landscape for US Patent 7,759,394 (diclofenac + alkali metal carbonate/bicarbonate for migraine with photophobia/phonophobia)
US 7,759,394 is a US method-of-treatment patent with claim scope centered on: (1) orally administering ~50 mg diclofenac (or salt) formulated with an alkali metal carbonate/bicarbonate; (2) rapid onset exposure characterized by narrow Cmax/tmax ranges and (3) clinical endpoints tied to migraine with photophobia and phonophobia within 2 hours, with a recurrent-migraine branch requiring sustained relief for at least 24 hours and in some claims “without rebound.” The estate is narrow in drug identity and dose but comparatively broad in delivery mechanics (liquid ingestion or water-dissolved/suspended powder), carbonate/bicarbonate excipient selection (alkali metal), and phenotype wording (photophobia, phonophobia, and migraine defined by periodic attacks including headache pain, nausea, photophobia, phonophobia).
If you are evaluating freedom-to-operate (FTO), licensing, or Paragraph IV risk for diclofenac migraine products, this patent’s practical “design-around” points are: different dose, different salt, different base excipient class, and especially different pharmacokinetic window (Cmax/tmax) and/or failure to meet the defined clinical endpoint timing (within 2 hours) and sustained-relief wording.
What patents protect diclofenac oral formulations for migraine with photophobia and phonophobia in the US?
US 7,759,394 claim theme. The patent is written as a set of layered method claims that repeatedly combine the same formulation core with specific PK and clinical timing outcomes. The formulation core is:
- Diclofenac or pharmaceutically acceptable salt at about 50 mg
- plus an alkali metal carbonate or bicarbonate
- administered orally
- formulation presented either as:
- liquid ingested with or without further mixing, or
- powder dissolved or suspended in water immediately before administration
Enabling PK constraints repeatedly recited across independent and dependent claims:
- Cmax (arithmetic mean) about 1500 to 2500 ng/mL (core method claims)
- tmax (arithmetic mean) about 10 to 25 minutes (core method claims)
- dependent alternatives: tmax 10 to 20 minutes and faster windows (e.g., tmax < 30 minutes)
- variability limits: inter-subject variability < ~70% for Cmax and/or tmax (claims 9–10 and 15–16)
Clinical endpoint framing:
- relieve photophobia and phonophobia within 2 hours
- for recurrent-migraine claims: sustained migraine relief for at least 24 hours
- for some recurrent-migraine claims: includes “without rebound”
- one claim set also includes nausea and the combined headache pain + nausea + photophobia + phonophobia within 2 hours
Claim coverage map by “claim element” (what must be true to infringe)
| Claim element |
What the patent requires (as written) |
Typical infringement risk driver |
| Indication/clinical endpoint |
migraine associated with photophobia and phonophobia; relieve within 2 hours |
Harder to design around if your label and clinician-use are aligned |
| Recurrent branch |
recurrent migraine requiring 24-hour treatment; sustained relief ≥24 hours; sometimes “without rebound” |
Strong factual dependency on trial outcomes and label language |
| Dose |
~50 mg diclofenac (or salt) |
Dose changes are a primary design-around |
| Drug identity |
diclofenac or pharmaceutically acceptable salt; dependent claims specify diclofenac potassium |
Switching to a non-covered salt or different active is a primary design-around |
| Excipient class |
alkali metal carbonate or bicarbonate |
Different base system outside “alkali metal carbonate/bicarbonate” reduces direct coverage |
| Form presentation |
liquid ingested or powder dissolved/suspended in water immediately before administration |
Different dosage form (e.g., enteric-coated tablet) helps avoid “immediately before” mechanics |
| PK window |
Cmax ~1500–2500 ng/mL and tmax ~10–25 min (and tighter dependent windows) |
PK window is a practical infringement gate |
| Dissolution threshold (dependent) |
>90% diclofenac dissolves completely in 50 mL water at 25°C under stirring 15 min at pH 6.8 |
Product performance testing can be decisive |
When does US Patent 7,759,394 lose exclusivity, and what does that mean for generic entry risk?
Term mechanics. US 7,759,394 is a granted US utility patent; enforcement and exclusivity are driven by:
- patent expiration under US utility term provisions (filing-date dependent)
- any terminal disclaimers and PTA (patent term adjustment)
- enforceability interruptions (reexamination, disclaimers)
- whether there are related patents still active
However, the prompt provides only the claims text and patent number, not the patent’s filing date, earliest priority date, PTA, or expiration date. Under the constraint that analysis must be complete and accurate, a definitive “loses exclusivity on [date]” statement cannot be produced from the information supplied.
What can be concluded from scope alone. For generic or follow-on products, the main risk timing remains tied to:
- whether the generic’s formulation and dosing regimen meet the patented PK/clinical constraints
- whether FDA approval relies on comparative bioequivalence that still lands within the claimed Cmax/tmax windows
If the patent is still within term, the risk is that the branded product can assert direct method infringement based on prescribing and administration consistent with the claims.
What are the key claim boundaries in US 7,759,394 for diclofenac migraine products?
Independent claim boundaries (practical “infringe or not” tests)
Claim 1 (core). Method of treating migraine associated with photophobia and phonophobia in a human patient within 2 hours of administration, requiring all of:
- Provide a liquid formulation comprising ~50 mg diclofenac (or salt) with alkali metal carbonate or bicarbonate
- Formulation is:
- powder dissolved/suspended in water immediately before administration, or
- liquid ingested (with or without further mixing)
- (Optionally, but recited) PK:
- Cmax arithmetic mean ~1500–2500 ng/mL
- tmax arithmetic mean ~10–25 min
- Orally administer to a patient suffering from migraine associated with photophobia and phonophobia
- Therefore relieve photophobia and phonophobia within 2 hours
Claims 13 and 20 (wider clinical endpoint language).
- Claim 13 also requires headache pain and nausea plus photophobia/phonophobia within 2 hours, and defines migraine as periodic attacks in a population including headache pain, nausea, photophobia, and phonophobia.
- Claim 20 treats headache pain, nausea, phonophobia and photophobia within two hours, and adds a broader Cmax/tmax window (Cmax mean ~1400–2500 ng/mL, tmax mean ~10–35 min) and still targets the same excipient and ~50 mg diclofenac core.
Claims 6 and 22 (recurrent migraine, sustained relief).
- Claim 6 focuses on recurrent migraine requiring 24-hour treatment and sustained relief for at least 24 hours.
- Claim 22 adds “without rebound” language for at least 24 hours.
Dependent claim “tighteners” that materially narrow or clarify infringement
-
Product-specific salt embodiment:
- Claim 3 and claim 8 and claim 17 specify diclofenac potassium.
-
Tighter tmax bins:
- Claim 4: tmax arithmetic mean 10–20 min
- Claim 11: same 10–20 min (recurrent branch)
- Claim 18: same 10–20 min (headache pain + nausea branch)
- Claim 21 and claim 23 include tmax < 30 min and Cmax >1500 ng/mL
-
Variability:
- Claims 9–10 and 15–16 require inter-subject variability < ~70% for Cmax and/or tmax.
-
Powder reconstitution mechanic:
- Claims 5, 12, 19 require powder dissolved/suspended in water immediately before administration.
-
Dissolution performance:
- Claims 24–25 require >90% diclofenac dissolves in a specified 50 mL water at 25°C under stirring 15 min at pH 6.8.
Design-around levers that are directly supported by claim language
- Move off ~50 mg diclofenac (dose change)
- Use a non-alkali-carbonate/bicarbonate base system or a different excipient classification (if outside “alkali metal carbonate or bicarbonate”)
- Change salt form away from diclofenac potassium (for embodiments that specifically require potassium)
- Use a dosage form that is not liquid/powder reconstituted “immediately before administration” as recited
- Shift bioavailability away from claimed PK windows (Cmax/tmax mean ranges, faster/slower profile)
- Fail to meet dissolution threshold (>90% in 50 mL, 25°C, pH 6.8, 15-minute stirring)
Which formulations and delivery systems are protected by US 7,759,394?
Protected delivery formats (as recited)
- Liquid formulation ingested with or without further mixing
- Powder formulation that is dissolved or suspended in water immediately before administration
The patent is not claiming generic “oral administration” broadly; it ties to a formulation presentation and a carbonate/bicarbonate-containing system.
Protected micro-mechanics: dissolution behavior
- Claim 24 and claim 25 require a performance-based dissolution profile:
90% of diclofenac dissolves completely in 50 mL water at 25°C under continuous stirring for 15 minutes at pH 6.8.
That language supports enforceability against products whose composition and formulation produce the same dissolution profile, even if the end product is a different physical format, provided the claim element “providing a pharmaceutical formulation” is met and the reconstitution context holds.
How does US 7,759,394 compare with other diclofenac US migraine patent estates?
A complete comparison requires:
- identifying all related US patents in the same family (continuations/divisionals) and
- mapping them to commercial products and FDA labels
- plus checking whether those patents overlap in formulation, method-of-use, and PK.
The prompt provides only one patent number and the claim text. With no family members, assignees, or citation list provided, a complete, accurate landscape comparison across the broader diclofenac migraine estates cannot be produced from the supplied inputs.
What patent litigation affects US 7,759,394 and which companies are challenging it?
This requires docket-level data (case captions, parties, allegations, Paragraph IV filings) and/or litigation histories. No litigation information is included in the prompt. Under the requirement to produce only complete and accurate results, this cannot be populated.
What is the Orange Book status of diclofenac migraine products covered by US 7,759,394?
Orange Book status requires:
- listing the exact FDA reference listed drug (RLD) and the NDA/ANDA numbers
- verifying whether US 7,759,394 is listed in Orange Book (patentability or exclusivity)
- and capturing listed expiration and regulatory exclusivity codes.
No NDA/ANDA identifiers or Orange Book listing details are provided, so a specific Orange Book status section cannot be generated accurately.
How strong is the patent estate for diclofenac + carbonate/bicarbonate migraine therapy?
Based solely on claim structure, strength features include:
- Tight formulation identity: diclofenac at ~50 mg with alkali metal carbonate/bicarbonate narrows to a specific medicinal chemistry and excipient class.
- Outcome coupling: clinical effect statements (relief within 2 hours; sustained ≥24 hours) can be used to support method infringement by demonstrating administration consistent with the claim and the resulting pharmacodynamic/clinical outcome.
- PK anchoring: multiple claims recite mean Cmax and tmax windows plus variability limits. For competitors, that creates an evidentiary target that can be tested in bioequivalence and/or dedicated studies.
Key vulnerability features (again, inferred only from claim text):
- Many descriptors appear as “found to achieve” windows. In litigation, the central dispute often becomes whether the competitor’s product meets those PK means and clinical timing when administered in the claimed way.
- The excipient class is broad (“alkali metal carbonate or bicarbonate”), but still a categorical limiter; competitors can try alternative alkalinizers.
A multi-patent-estate strength analysis cannot be completed without additional patents, prosecution history, and family data.
What generic entry risks exist for the diclofenac migraine indication with photophobia and phonophobia?
Risk profile of a generic/follow-on
If a generic product:
- uses ~50 mg diclofenac,
- includes an alkali metal carbonate/bicarbonate,
- is administered as a liquid or reconstituted powder “immediately before administration,”
- and shows Cmax/tmax mean values and dissolution behavior that fall into the claimed windows,
- and the intended use or actual method-of-use prescribing aligns with the patented clinical endpoints (within 2 hours for photophobia/phonophobia; sustained relief for at least 24 hours for recurrent migraine),
then the generic faces direct method-of-use infringement exposure under US 7,759,394.
Lowering exposure through design
- A product positioned with different dose strength (not “about 50 mg”), different salt embodiment, different alkalizer class outside carbonate/bicarbonate, or different PK profile can move outside the claim boundaries.
- A product that does not rely on the same clinical timing claims (label and prescribing) may reduce direct method exposure, though not always if the claims are construed to cover the physiology regardless of label wording.
Key Takeaways
- US 7,759,394 is a method-of-treatment patent focused on oral diclofenac (~50 mg) formulated with alkali metal carbonate/bicarbonate for migraine involving photophobia and phonophobia, with rapid relief within 2 hours.
- The claim set adds a recurrent-migraine pathway requiring ≥24-hour sustained relief and sometimes “without rebound.”
- Claim scope is operationalized through PK constraints (mean Cmax and tmax ranges), variability limits, and dissolution performance (>90% in defined conditions).
- Primary design-around levers supported by the claim text are: dose, salt form, base excipient class, dosage form/reconstitution mechanics, PK profile, and dissolution behavior.
FAQs
-
Does US 7,759,394 require diclofenac potassium or any diclofenac salt?
The core claims require diclofenac or a pharmaceutically acceptable salt; dependent claims specify diclofenac potassium.
-
Is the tmax limitation in claim 1 strict or optional?
Claim 1 states PK targets as “optionally has been found to achieve,” but other dependent claims narrow tmax windows.
-
What elements are most likely to be disputed in infringement: PK or clinical outcomes?
The patent repeatedly ties infringement to “found to achieve” PK windows and timing outcomes (within 2 hours; sustained ≥24 hours), so both are frequently central.
-
Can a different oral dosage form avoid infringement?
The claims are tied to liquid ingestion or powder dissolved/suspended immediately before administration, plus dissolution testing in certain dependent claims.
-
What is the role of “without rebound” in the recurrent-migraine claims?
It is an added clinical limitation in the recurrent branch and can be a focal point for trial outcome and label alignment.
References
- U.S. Patent 7,759,394.
